[18F]THK-5351 PET imaging of tau deposits in neurological disorders

Trial Profile

[18F]THK-5351 PET imaging of tau deposits in neurological disorders

Phase of Trial: Phase III

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs Fluorine 18 THK 5351 (Primary)
  • Indications Neurodegenerative disorders; Neurological disorders
  • Focus Diagnostic use
  • Most Recent Events

    • 14 Jul 2018 Planned number of patients changed from 140 to 160.
    • 11 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 13 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top